Live moderated webcast with John Climaco, Chief Executive Officer of CNS Pharmaceuticals, on Monday, August 26th at 12:00 p.m. ET
Participants will have the opportunity to submit questions live during the Q&A portion of the segment or submit questions in advance.ce of the segment by email (email protected)
HOUSTON, TX / ACCESSWIRE / August 22, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”), a biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will participate in a Virtual Investor CEO Connect segment on Monday, August 26, 2024 at 12:00 p.m. ET.
During the virtual event, Mr. Climaco will give a short presentation followed by an interactive question-and-answer session. Investors and interested parties will have the opportunity to submit questions live during the segment. Questions can also be submitted via email in advance of the segment. (email protected)Mr. Climaco will answer as many questions as possible in this section.
A live video webcast of the presentation will be available on the Events page in the Investors section of the Company’s website (cnspharma.com). A replay of the webcast will be available two hours after the live presentation and will be accessible for 90 days.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a series of cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline that appears to cross the blood-brain barrier. Berubicin is currently being developed to treat a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
For more information, visit www.CNSPharma.com. You can also connect with the company on X, Facebook and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenne Thomas
833-475-8247
(email protected)
SOURCE: CNS Pharmaceuticals, Inc.
